Dermata Therapeutics, Inc. (DRMAW) Stock Price & Analysis

Dermata Therapeutics, Inc. (DRMAW) fell 4.81% to USD 0.01 as of July 26, 2026 at 10:09 UTC, according to Nexqual real-time market data.

DRMAW last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 200 shares. Market capitalization is —, with a 52-week range of USD 0.01–0.01 (NCM). Source: Nexqual, July 26, 2026 at 10:09 UTC.

Key Statistics (as of July 26, 2026 at 10:09 UTC)

Analyst Ratings (DRMAW)

Wall Street analysts rate DRMAW "None", per Nexqual as of July 26, 2026 at 10:09 UTC.

Earnings (DRMAW)

Source: Nexqual, July 26, 2026 at 10:09 UTC.

Financials & Fundamentals (DRMAW)

Source: Nexqual, July 26, 2026 at 10:09 UTC.

Financial Health Score (DRMAW)

Nexqual rates Dermata Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 10:09 UTC.

Ownership (DRMAW)

Source: Nexqual, July 26, 2026 at 10:09 UTC.

Leadership (DRMAW)

Dermata Therapeutics, Inc. is led by Gerald T. Proehl (age 66), Founder, President, CEO & Chairman, per Nexqual as of July 26, 2026 at 10:09 UTC.

Major Backers & Investors (DRMAW)

Notable institutional backers of Dermata Therapeutics, Inc. include Boothbay Fund Management, LLC, according to Nexqual as of July 26, 2026 at 10:09 UTC.

Active Investors

Source: Nexqual, July 26, 2026 at 10:09 UTC.

From Dermata Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)

Key Strengths & Strategy (as disclosed to the SEC)

• The combination of a proprietary harvesting protocol, developed by our exclusive supplier, and the post-harvest processing procedures, produce an ingredient that we believe optimizes the mechanical components, which are silica microstructures also called spicules, as well as the organic components of Spongilla , while eliminating any harmful bacteria that could be found in many freshwater or marine sponges.
• With our proprietary harvesting protocols and manufacturing procedures, we are able to take Spongilla lacustric raw material and leverage the combination of evolution and scientific innovation to create a unique product we like to call, Bioneedle.
• Our product development strategy is centered on the scalable use of our proprietary Bioneedle as the foundation for any well-rounded skincare routine.
• BDS works by first topically applying our proprietary sponge powder to the treatment area wherein the mechanical Bioneedles penetrate the skin, thereby creating millions of microchannels into the dermis similar to the Image 4 below.

Partnerships

• One such location is the Volga River, where we have signed an exclusive supply agreement with one of the larger known suppliers of wild harvested Spongilla raw material for our Tome skincare line, which we believe provides us with a reliable source of our supply of Spongilla raw material for the foreseeable future.
• In February 2020, we signed an exclusive supply agreement with this supplier of Spongilla raw material .

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 10:09 UTC. This page is informational and not investment advice.